WHO Goodwill Ambassador Issues Rallying Cry to Accelerate International Efforts to Eliminate Leprosy: "The Last Mile Starts Now"
TOKYO, May 22, 2026 /PRNewswire/ -- Yohei Sasakawa has issued a rallying cry for the international community to step up efforts for a world without leprosy. "The last mile starts now," he said, addressing a reception held in Geneva on May 18 during...
Lundbeck receives orphan drug designation in Japan for asedebart for the treatment of patients with congenital adrenal hyperplasia and Cushing's disease
Congenital adrenal hyperplasia (CAH) and Cushing's disease (CD) are rare disorders characterized by excess adrenocorticotropic hormone (ACTH) produced in the brain1,2 Current treatments are limited by suboptimal disease control and treatment-related...
OncoC4 announces first participant's dosing in Phase 1/2 clinical trial of ONC-841 for the treatment of Alzheimer's disease
ROCKVILLE, Md., April 9, 2026 /PRNewswire/ -- OncoC4 Inc., a late clinical stage biopharmaceutical company, today announced first participant's dosing following the clearance of the Investigational New Drug (IND) application for a Phase 1/2 clinical...
iRegene Hits Dual Global Firsts: U.S. Patient Dosed in Phase IIa for NouvNeu001 in Parkinson's and First Enrollment in China's Randomized MSA Trial for NouvNeu004
CHENGDU, China, Feb. 23, 2026 /PRNewswire/ -- The global race to treat neurodegenerative diseases has reached a new tempo as iRegene Therapeutics pushes its cell therapy pipeline into key clinical stages in the U.S. and China. Concurrently, the...
UniXell Biotechnology announces the first patient dosed with UX-DA001, an investigational autologous iPSC based cell therapy for the treatment of Parkinson's disease, in its Phase 1 study
SHANGHAI, May 23, 2025 /PRNewswire/ -- Shanghai UniXell Biotechnology Co., Ltd. (UniXell Biotech), a biotech company dedicated to innovative cell therapies, announced the successful first administration of its proprietary Parkinson's disease cell...
